Why the study?
Human noroviruses lack specific antivirals or vaccines, and more insight was needed into how macrocyclic inhibitors interact with norovirus 3CL protease and how ring size affects pharmacological activity and cellular permeability.
Structural analysis suggests that the macrocyclic scaffold of norovirus 3CL protease inhibitors may impede optimal binding by disrupting cross-talk between S2 and S4 subsites.
Answers are grounded in this paper and cite their sources.
Structural insights into NV 3CLpro may aid inhibitor design; leaves open clinical translation for norovirus antivirals.
Human noroviruses are the primary cause of outbreaks of acute gastroenteritis worldwide. The problem is further compounded by the current lack of norovirus‐specific antivirals or vaccines. Noroviruses have a single‐stranded, positive sense 7 to 8 kb RNA genome which encodes a polyprotein precursor that is processed by a virus‐encoded 3C‐like cysteine protease (NV 3CLpro) to generate at least six mature nonstructural proteins. Processing of the polyprotein is essential for virus replication, consequently, NV 3CLpro has emerged as an attractive target for the discovery of norovirus therapeutics and prophylactics. We have recently described the structure‐based design of macrocyclic transition state inhibitors of NV 3CLpro. In order to gain insight and understanding into the interaction of macrocyclic inhibitors with the enzyme, as well as probe the effect of ring size on pharmacological activity and cellular permeability, additional macrocyclic inhibitors were synthesized and high resolution cocrystal structures determined. The results of our studies tentatively suggest that the macrocyclic scaffold may hamper optimal binding to the active site by impeding concerted cross‐talk between the S2 and S4 subsites.
No takes yet. Share an insight, caveat, or question.
Kankanamalage et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: